Golden State Wealth Management’s NovoCure NVCR Stock Holding History

Golden State Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33	Hold	3	–	–	﹤0.01%	1586
2025 Q4	$39	Hold	3	–	–	﹤0.01%	1656
2025 Q3	$39	Hold	3	–	–	﹤0.01%	1645
2025 Q2	$53	Hold	3	–	–	﹤0.01%	1557
2025 Q1	$53	Hold	3	–	–	﹤0.01%	1575
2024 Q4	$89	Buy	+3	New	+$63	﹤0.01%	1487
2021 Q1	–	Sell	-1,406	Closed	-$243K	–	225
2020 Q4	$243K	Buy	1,406 +6	+0.4%	+$821	0.07%	206
2020 Q3	$156K	Buy	+1,400	New	+$112K	0.05%	214
2020 Q2	–	Sell	-2,800	Closed	-$189K	–	664
2020 Q1	$189K	Buy	+2,800	New	+$221K	0.08%	161
2019 Q2	–	Sell	-400	Closed	-$19K	–	1133
2019 Q1	$19K	Buy	+400	New	+$19.3K	0.01%	642

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Golden State Wealth Management's NVCR Position: Q1 2026 in Review

Golden State Wealth Management held its NovoCure (NVCR) position steady in Q1 2026 at 3 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Golden State Wealth Management first reported a position in NVCR in Q1 2019 and has held it in 10 quarters since. The position peaked at $243K in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Golden State Wealth Management held 3 shares of NovoCure worth $33 as of Q1 2026.
Golden State Wealth Management left its NovoCure share count unchanged in Q1 2026.
NovoCure made up ﹤0.01% of Golden State Wealth Management's portfolio in Q1 2026, its #1586 holding.
Golden State Wealth Management first reported a position in NovoCure in Q1 2019 and has held it in 10 quarters since.
Golden State Wealth Management's NovoCure position peaked at $243K in Q4 2020.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.